Genetic predictors of interindividual variability in hepatic CYP3A4 expression

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 1088-1099

  Lamba, Vishal ^a   Panetta, John C ^a   Strom, Stephen ^b   Schuetz, Erin G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; HEPATOCYTE NUCLEAR FACTOR 3BETA; HEPATOCYTE NUCLEAR FACTOR 3GAMMA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR;

ALLELE; ARTICLE; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LIVER; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRINUCLEOTIDE REPEAT; WILD TYPE;

CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HUMANS; LINEAR MODELS; LIVER; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS; TRINUCLEOTIDE REPEATS;

EID: 77249101725     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160804     Document Type: Article

References (41)

1. Abderrahmani A, Chèvre JC, Otabe S, Chikri M, Hani EH, Vaxillaire M, Hinokio Y, Horikawa Y, Bell GI, and Froguel P (2000) Genetic variation in the hepatocyte nuclear factor-3beta gene (HNF3B) does not contribute to maturity-onset diabetes of the young in French Caucasians. Diabetes 49:306-308.
2. Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, and Kaestner KH (2008) Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat Med 14:828-836.
3. Bochkis IM, Schug J, Rubins NE, Chopra AR, O'Malley BW, and Kaestner KH (2009) Foxa2-dependent hepatic gene regulatory networks depend on physiological state. Physiol Genomics 38:186-195.
4. De Abreu FB, Pirolo LJ, Canevari Rde A, Rosa FE, Moraes Neto FA, Caldeira JR, Rainho CA, and Rogatto SR (2007) Shorter CAG repeat in the AR gene is associated with atypical hyperplasia and breast carcinoma. Anticancer Res 27:1199-1205.
5. Dixon RL, Hart LG, and Fouts JR (1961) The metabolism of drugs by liver microsomes from alloxan-diabetic rats. J Pharmacol Exp Ther 133:7-11.
6. Friedman JR and Kaestner KH (2006) The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci 63:2317-2328.
7. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, and Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331-334.
8. Gebhardt F, Zänker KS, and Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 14. J Biol Chem 274:13176-13180.
9. Jover R, Bort R, Gómez-Lechón MJ, and Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16:1799-1801.
10. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, and Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528.
11. Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, and Talianidis I (2006) Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev 20:2293-2305.
12. Lamba J, Lamba V, Strom S, Venkataramanan R, and Schuetz E (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36:169-181.
13. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins P, and Schuetz E (2006) MDR1 genotype is associated with Hepatic CYP3A4 basal and induction phenotype.Clin Pharmacol Therap 79:325-338.
14. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
15. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, and Schuetz EG (2004) PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:251-265.
16. Lee CS, Friedman JR, Fulmer JT, and Kaestner KH (2005) The initiation of liver development is dependent on Foxa transcription factors. Nature 435:944-947.
17. Li Z, White P, Tuteja G, Rubins N, Sackett S, and Kaestner KH (2009) Foxa1 and Foxa2 regulate bile duct development in mice. J Clin Invest 119:1537-1545.
18. Lim YP and Huang JD (2008) Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 23:14-21.
19. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
20. Martínez-Jiménez CP, Gómez-Lechón MJ, Castell JV, and Jover R (2005) Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol Pharmacol 67:2088-2101.
21. Martínez-Jiménez CP, Jover R, Donato MT, Castell JV, and Gómez-Lechón MJ (2007) Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 8:185-194.
22. Nakamura K, Moore R, Negishi M, and Sueyoshi T (2007) Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J Biol Chem 282:9768-9776.
23. Nickerson DA, Tobe VO, and Taylor SL (1997) PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 25:2745-2751.
24. Odom DT, Dowell RD, Jacobsen ES, Gordon W, Danford TW, MacIsaac KD, Rolfe PA, Conboy CM, Gifford DK, and Fraenkel E (2007) Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat Genet 39: 730-732.
25. Ourlin JC, Jounaidi Y, Maurel P, and Vilarem MJ (1997) Role of the liver-enriched transcription factors C/EBP alpha and DBP in the expression of human CYP3A4 and CYP3A7. J Hepatol 26 (Suppl 2):54-62.
26. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, and Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
27. Rausa FM, Tan Y, Zhou H, Yoo KW, Stolz DB, Watkins SC, Franks RR, Unterman TG, and Costa RH (2000) Elevated levels of hepatocyte nuclear factor 3beta in mouse hepatocytes influence expression of genes involved in bile acid and glucose homeostasis. Mol Cell Biol 20:8264-8282.
28. Rodríguez-Antona C, Bort R, Jover R, Tindberg N, Ingelman-Sundberg M, Gómez-Lechón MJ, and Castell JV (2003) Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol Pharmacol 63:1180-1189.
29. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nürnberg P, Zanger UM, and Wojnowski L (2007) Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 8:443-453.
30. Schuetz EG (2004) Lessons from the CYP3A4 promoter. Mol Pharmacol 65:279-281.
31. Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, and Schinkel AH (2000) Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 57:188-197.
32. Shimada T, Iwasaki M, Martin MV, and Guengerich FP (1989) Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res 49:3218-3228.
33. Sidhu JS and Omiecinski CJ (1999) Insulin-mediated modulation of cytochrome P450 gene induction profiles in primary rat hepatocyte cultures. J Biochem Mol Toxicol 13:1-9.
34. Tabassum R, Chavali S, Dwivedi OP, Tandon N, and Bharadwaj D (2008) Genetic variants of FOXA2: risk of type 2 diabetes and effect on metabolic traits in North Indians. J Hum Genet 53:957-965.
35. Takeo C, Negishi E, Nakajima A, Ueno K, Tatsuno I, Saito Y, Amano K, and Hirai A (2005) Association of cytosine-adenine repeat polymorphism of the estrogen receptor-beta gene with menopausal symptoms. Gend Med 2:96-105.
36. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4 alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
37. Uetzmann L, Burtscher I, and Lickert H (2008) A mouse line expressing Foxa2-driven Cre recombinase in node, notochord, floorplate, and endoderm. Genesis 46:515-522.
38. Watanabe M, Kumai T, Matsumoto N, Tanaka M, Suzuki S, Satoh T, and Kobayashi S (2004) Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver. J Pharmacol Sci 94:459-462.
39. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988.
40. Wolfrum C, Asilmaz E, Luca E, Friedman JM, and Stoffel M (2004) Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432:1027-1032.
41. Wortham M, Czerwinski M, He L, Parkinson A, and Wan YJ (2007) Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35:1700-1710.